Fulcrum Therapeutics (FULC)

• Market cap: $825M
• 1 day: -3.25%
• 5 days: -14.79%
• 1 month: 29.53%
• 3 months: 71.23%
• 6 months: 83.82%
• Year to date: 158.26%
• 1 year: 182.81%
• 5 years: -5.37%
• 10 years: -7.41%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45